Mining PeptideAtlas for Biomarkers and Therapeutics in Human Disease

Author(s): Sarah Killcoyne, Eric W. Deutsch, John Boyle

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 6 , 2012

Become EABM
Become Reviewer


Mass spectrometry information has long offered the potential of discovering biomarkers that would enable clinicians to diagnose disease, and treat it with targeted therapies. PeptideAtlas currently provides access to large-scale spectra data and identification information. This data, and the generation of targeted peptide information, represents the first step in the process of locating disease biomarkers. Reaching the goal of clinical proteomics requires that this data be integrated with additional information from disease literature and genomic studies. Here we describe PeptideAtlas and associated methods for mining the data, as well as the software tools necessary to support large-scale integration and mining.

Keywords: SRM, Mass spectrometry, proteomic, visualization, data mining, PeptideAtlas, Streptococcus pyogenes, Glioblastoma, Integration, Cytoscape

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [748 - 754]
Pages: 7
DOI: 10.2174/138161212799277833
Price: $65

Article Metrics

PDF: 8